is a multi7factorial interdisciplinary methodology aiming to optimize individual medication therapy throughout the hospital stay. IMM has shown to reduce hospital visits and drug related hospital readmissions. Using the IMM model as a template, we designed an intervention to improve medication safety in hospitals, and a service to improve communication across the secondary and primary care
interface. This paper presents the study protocol to explore the effects of interdisciplinary collaboration with regards to healthcare use, health related quality of life (HRQoL) and medication appropriateness in elderly patients.
& #% #%#$ " : A total of 500 patients aged 70+ will be included and randomized (1:1) to standard care or the intervention. The intervention comprises five steps mainly performed by pharmacists: i) medication reconciliation at admission, ii) medication review during hospital stay, iii) patient counselling about the use of medicines, iv) comprehensible and patient7friendly medication list with explanations in discharge summary and v) post7discharge phone calls to the primary care level.
The primary outcome is the difference in the rate of emergency medical visits (acute rehospitalization + visits to emergency department) 12 months after discharge in intervention and control patients.
Secondary outcomes include time to first re7hospitalization, length of hospital stay, mortality, hip fractures, strokes, medication changes, health7related quality of life, and medication appropriateness)
Patient inclusion started in September 2016.
"' #% " *"%# "&%) The trial was approved by the Norwegian Centre for Research Data and the Norwegian Data Protection Authority.
!"#$ ! +" !# "&% % *, !) ClinicalTrials.gov (NCT02816086).
--No randomized controlled study investigating the effects of implementing an IMM based intervention in the Norwegian health care setting has been published.
-Nationwide health care registers will enable us to collect high quality data for our primary endpoint.
-Collecting outcomes for a period of one year after discharge allows us to measure sustainable effects of our intervention.
-A limitation is that including control and intervention patients from the same wards may introduce education and contamination bias. -Our intervention is complex, and the study will not answer if there is one specific part of the intervention that is responsible for any observed effects.
Healthcare systems across the world are challenged by an aging population. Aging is frequently accompanied by morbidity which increases the need for pharmacotherapy. The increased complexity of medication regimes combined with frailty, reduced cognitive function and changes in pharmacokinetics and -dynamics, increases the risk of adverse drug effects (ADEs) and other drug7 related problems (DRPs) in this population 1 2 .
A drug7related problem (DRP) is 'an event or circumstance involving drug therapy that actually or potentially interferes with desired health outcomes' 3 . DRPs include inappropriate prescribing (drug, dose, dosage frequency, and dosage form), drug7drug interactions, adverse drug reactions, wrong administration, need for monitoring as well as non7adherence to therapy. DRPs occur frequently in elderly 4 5 , and are associated with increased risk of hospitalization, morbidity and mortality 678 . For instance, adverse drug events alone contribute to 30740% of acute hospital admissions in the elderly 9 10 , many of them being preventable 11714 .
Communication barriers across primary and secondary care, multiple prescribers, fragmentation of care, and frequent transitions across care levels, make hospitalized elderly in particular risk of drug induced harm 15 16 . To improve the medicine management process in hospitals, pharmacist dependent methods like medication reconciliation (MedRec), medication review and patient education have been developed and studied 17720 . The Integrated Medicines Management (IMM) model is based on interdisciplinary collaboration where clinical pharmacists work together with physicians, nurses and patient seeking to optimize medication therapy by preventing and solving DRP 21 22 . In the IMM model different services like MedRec, medication review, patient counselling and dissemination of correct medication information at transition points are merged together in a systematic way 21 23 . In Northern
Ireland, the implementation of the IMM model in hospitals has led to a reduced length of hospitalization and an increased time to re7hospitalization compared to standard care 23 24 . Also in Sweden, implementing IMM in single hospital settings has been associated with a reduction in hospital visits and drug7related re7admissions, improved communication of medication information at transition points and improved quality of drug therapy 21 25 26 . In Norway, hospital pharmacies providing pharmaceutical care services have since 2010 been based on the methods embraced by the IMM methodology 27 . However, no randomized controlled studies investigating the effects of implementing the IMM7model in the Norwegian health care system have been published. Based on the IMM model, we have designed an interdisciplinary collaboration structure aiming to optimize medication therapy in hospitals and improve the communication of medication7related issues between secondary and primary care. The aim of the study is to explore the effects of this collaboration structure on healthcare use, health related quality of life (HRQoL) and medication appropriateness in elderly patients.
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The primary objective is to investigate the effects of the interdisciplinary collaboration on rate of emergency medical visits (acute readmissions and visits to emergency departments (ED) 12 months after hospital discharge.
Due to the clinical approach of the study, the complexity of the intervention and the possibility to link with health registers, secondary objectives include to investigate the effects on; self7reported quality of life, acute readmissions, length of index hospital stay, time to first re7hospitalization, rate of visits to general practitioner (GP), mortality rate, medication appropriateness, number of drug7related re7
hospitalizations, drug changes, hip fractures and stroke
This protocol was developed in accordance with the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 statement 28 (see online supplement for the SPIRIT 2013 checklist).
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This is a non7blinded randomized controlled trial with an intervention group and a control group (1:1 ratio). The intervention group receives the new intervention, while the control group will receive standard care, see Figure 1 . Study enrolment started in September 2016.
The study is carried out at two different locations at the University hospital of North7Norway (UNN); UNN Tromsø and UNN Harstad.
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All acutely admitted patients are screened for eligibility by study pharmacists. $"+","$" '!" !"# Inclusion criteria are: age ≥70 years, acutely admitted and willing to provide written informed consent (patient or next of kin). Exclusion criteria includes: admitted to the study ward more than 72 hours before evaluation for eligibility, moved to and discharged from other wards during the index stay, inability to understand Norwegian (patient or next of kin), considered terminally ill or short life expectancy, planned discharged on the inclusion day, occupying a bed in a study ward but under the care of physicians from a non7study ward, and patients where an intervention from a study pharmacist is considered necessary for ethical reasons (before randomization or in control group).
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After collecting baseline data, included patients are randomized into the two study arms using a web7
based service supplied by a third party. The randomization blocks sizes will be concealed and permuted. We stratify by study site. As pharmacists are only involved in intervention patients, blinding of group allocation is impossible both to the patients, pharmacists and medical team.
However, the primary analysis will be performed by an investigator blinded for group allocation.
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Patients assigned to standard care receive treatment from a team consisting of physicians, nurses, nurse assistants, sometimes occupational therapists and physiotherapists. Standard care includes many of the same elements as the intervention, but are less extensive, not standardized and performed by physicians or nurses. Study pharmacists are not involved in any clinical work concerning patients randomised to the control group Regarding MedRec at admission, this service is currently being implemented in hospitals nationwide as a part of the national patient's safety initiative. The hospital procedure state that MedRec should be performed by a physician at admittance, but local data show that adherence to the procedure is low (data not published). At discharge, the procedures denote that assessments, amendments and recommendations made during hospitalization, together with an updated medication list, should be reported to the GP in an electronical discharge summery. Ward nurses call the home care services or nursing homes to inform about current medication therapy and to investigate the need for prescriptions or medications to be sent home with the patient. The GP is responsible for the follow7up of discharge summary as well as renewal and revision of prescribed medications. Patients for whom special care is considered necessary at home are referred to a specialized patient care team before or at discharge. These teams may include a pharmacist, which may supply clinical services.
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Patients randomized to the intervention group receive a service provided by a pharmacist including 1)
MedRec at admission, 2) medication review and monitoring during the hospital stay, 3) patient counselling designed to meet the needs of each individual patient, 4) MedRec at discharge together with an updated and structured medication list given to patients and submitted to primary care at discharge, and 5) study pharmacists call the patient´s GP or nurses in home care service/nursing home to inform about and discuss current drug therapy and recommendations, see Figure 2 .
Step 1: Medication reconciliation (MedRec)
MedRec is performed using a standardized MedRec tool. The tool eases information collection, e.g., documentation of information and information sources, and includes questions about patients' practical handling, knowledge about medications, as well as medication adherence 21 29 . Patients that handle their own medication are, if possible, interviewed. If not, information about medication use is collected from other relevant sources, i.e. medication charts from GP`s, national electronic medical records, local pharmacies, home care services, nursing homes or next of kin. These sources are used to confirm medication information after patient interviews in case of uncertainties. Any adherence or medication information issues registered during MedRec is acted upon during patient counselling or at hospital discharge (Step 3).
During MedRec, the study pharmacists also perform a standardized symptom evaluation to be used in
Step 2. The evaluation seeks to answer whether and to what degree patients are experiencing any of the following ten symptoms that may be related to medication therapy: dizziness, general fatigue, memory deficiency, sleeping difficulties, dry mouth, nausea, constipation, micturition difficulties, pain or cough. If patients are not capable of answering the questions, information are obtained from relatives or associated health care workers.
Step Step 3: Patient counselling
For patients who will handle their own medication after discharge, a patient counselling session are arranged before discharge. The patient receives an updated medication list which will be discussed and explained. The pharmacist will focus upon changes made during hospitalization and reasons for these changes. The patient is also encouraged to ask questions about their medications. Any medication adherence, handling or information issues identified during the hospital stay are also focused upon. If
DRPs are identified during this counselling session, they are discussed with the responsible physician.
This step is in addition to the standard discharge meeting between the physician and the patient.
Step 4: Structured and detailed medication list in discharge summaries
The discharge summary normally includes an updated overview of medications to be used after discharge. For intervention patient's pharmacists draft this list in accordance with hospital procedures and the national patient safety program and make sure it is reconciled, structured, correct according to amendments done during hospitalization and contains information and explanations about medication changes made during hospitalization as well as recommendations and follow7up issues. The ward physician uses this draft when preparing the discharge summary.
Step 5: Communication with primary care
Pharmacist make a phone call to the patient`s GP within a week after hospital discharge. The aim is to inform about and discuss current drug therapy and recommendations, so that these are acted upon and implemented. For patients where the home care services or the nursing home administer the medications, in addition to the GP, the responsible nurse is contacted by phone on the day of discharge to inform about medication changes, prescription and monitoring needs and other medication related For patient where no change in medications have been made during hospital stay and no need for follow up have been identified, step 5 is not carried out.
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Primary outcome
The primary outcome is the rate of the composite endpoint "acute readmissions and ED visits" 12 months after discharge from the index hospital stay. An acute readmission is defined as any subsequent admission following the index admission excluding elective readmissions.
Secondary outcomes
1. Change in self7reported health7related quality of life (HRQoL) from discharge to 1, 6 and 12 months after hospital discharge in the intervention group compared with control group.
2. Length of index hospital stay, difference between intervention or control patients.
3. Time to first acute readmission after discharge from index hospital stay in intervention group compared with control group (up to 12 months follow7up).
4. The proportion of patients readmitted acutely within 30 days (a national quality indicator in Norway).
5. GP visit rate during 12 months' follow7up in intervention group compared with control group.
6. Mortality rate during 12 months' follow7up in intervention group compared with control group.
7. Change in total score from admission to discharge of the Medication appropriateness index (MAI) in intervention compared to control patients. leading to a hospitalization will be counted as a hospitalization. We will collect data from all registers for the period 12 months before and 12 months after index hospitalization to enable adjustment for pre7study patterns.
In addition to the data on prescriptions collected from NorPD, updated lists of medications in use is collected from GP offices or nursing homes as appropriate at 3 and 12 months after hospital discharge.
Inappropriate prescribing
The medications list at hospital admission, at discharge and at 3 and 12 months after discharge will retrospectively be subject for application of the following scoring tools to identify possible inappropriate prescribing by an investigator blinded for group allocation: NORGEP7NH 31 , STOPP and START
32
. The medication lists at admission and at discharge will be scored in accordance with the medication appropriateness index (MAI) by an experience pharmacist blinded to group allocation 33 34 .
Health7related quality of life (HRQoL)
We use EQ75D and EQ7VAS to measure HRQoL 35 . This is performed by a study nurse blinded to group allocation. The measurement is performed at the end of the hospital stay and 1, 6 and 12 months' post discharge. The study nurse call patients and perform the interview by phone. Patients 
Drug7related re7hospitalizations
An interdisciplinary group of physicians and pharmacists will retrospectively assess whether the patients first re7hospitalization was related to his/her medications and whether it could have been prevented. This will be performed blinded to group allocation.
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All data except registry data is entered manually into a Microsoft Access database. A random sample of patients will be drawn for control of data quality. Patient7ID is removed from all paper records and given consecutive study numbers. A list linking patient7IDs to study numbers is stored electronically in the hospital research server, separate from the Microsoft Access database. Only study personnel have access to the research server. Study papers used during work are kept at the hospital in accordance with hospital patient protection routines.
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We will use IBM SPSS Statistics for data analysis. Data will be analysed according to intention7to7
treat (ITT) principles, and the report of results will follow the CONSORT guidelines 36 . All participants will be included in the analysis, regardless of whether they completed the intervention or not. A per protocol analysis will also be performed. Descriptive statistics for both study arms, and the total study population will be provided.
The primary analysis will be a Poisson regression of the rate of the composite end7point during 12 months' post discharge between the two study groups taking into account censoring of study participants. Adjustment for study site will be conducted. A two7sided alpha level of 5% will be used.
We also plan to perform a secondary analysis of the primary endpoint using the proportion of patients fulfilling the composite endpoint and a survival analysis of the time to reach the composite end7point.
In all analyses, adjustment for baseline variables will be conducted if appropriate.
We will analyse secondary outcomes applying appropriate statistical tests, e.g., comparison between study arms by logistic regression analysis for binary responses and using Cox proportional hazards models for survival data. Continuous responses will be analysed using linear regression. A two7sided 5% significance level will be applied, with no adjustments for multiplicity. informed consent or not.
The trial will be conducted in compliance with the protocol, the principles of Good Clinical Practice and the Helsinki declaration. The study has approval from the Norwegian Centre for Research data and the Norwegian Data Protection Authority to collect, store and link research data. Only patients who supply a written informed consent are included in the study. If patients are not able to consent, the next of kin is asked. If a patient is in delirium at hospital admission, the next of kin is contacted for a written consent. When the patient is out of delirium, he/she is asked to give the written consent themselves. Those who refuse is excluded from the study.
We will not expose the patient for any new clinical intervention that may put the patient at risk. In fact, some of the elements/procedures included in the intervention have already been shown to reduce drug7related hospitalizations, and visits to emergency departments 19 20 . Nevertheless, our intervention brings a new health7care profession, the pharmacist, into the team for whom the patient will have to relate to. We anticipate that patients feeling uncomfortable with this will deny study participation.
We aim to publish study results in international peer7reviewed open access journals.
6 -
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. " o n l y 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47 o n l y o n l y -National health care registries will enable us to collect high quality data for several outcomes including the primary.
-Collecting outcomes for a one7year period after discharge allows us to measure sustainable effects of our intervention. -By including control and intervention patients from the same wards we may introduce education and contamination bias, which is a limitation.
-We are implementing a complex intervention, and this study will not allow for studying whether any of the specific steps are more of less responsible for any observed effects.
Healthcare systems across the world are challenged by an aging population. Aging is frequently accompanied by morbidity, which increases the need for pharmacotherapy. The increased complexity of medication regimes combined with frailty, reduced cognitive function and changes in pharmacokinetics and -dynamics, increases the risk of adverse drug events and other drug7related problems (DRPs) in this population 1 2 .
A DRP is "an event or circumstance involving drug therapy that actually or potentially interferes with desired health outcomes" 3 . DRPs include inappropriate prescribing (drug, dose, dosage frequency, and dosage form), drug interactions, adverse drug reactions, wrong administration, need for monitoring as well as non7adherence to medication therapy. DRPs occur frequently in the elderly 4 5 , and are associated with an increased risk of hospitalization, morbidity and mortality 678 . For instance, adverse drug events alone contribute to 30740% of acute hospital admissions in the elderly 9 10 , many of them being preventable 11714 .
Communication barriers across primary and secondary care, multiple prescribers, fragmentation of care, and frequent transitions across care levels make hospitalized elderly in particular risk of drug7 induced harm 15 16 . To improve the medicines management process in hospitals, pharmacist dependent methods like medication reconciliation (MedRec), medication review and patient education have been developed and studied 17720 . The Integrated Medicines Management (IMM) model is based on interdisciplinary collaboration where clinical pharmacists work together with physicians, nurses and patients aiming to optimize medication therapy by preventing and solving DRPs 21 22 . In the IMM model different services like MedRec, medication review, patient counselling and dissemination of correct medication information at transition points are merged together in a systematic way 21 23 . In
Northern Ireland, the implementation of the IMM model in hospitals has led to a reduced length of hospital stay and an increased time to re7admission compared to standard care 23 24 . Also in Sweden, implementing IMM in single hospital settings has been associated with a reduction in readmissions and drug7related re7admissions, improved communication of medication information at transition points and improved quality of medication therapy 21 25 26 . In Norway, pharmaceutical care services in hospitals have since 2010 been based on the methodology embraced by the IMM model 27 . However, no randomized controlled trail investigating the effects of implementing the IMM model in the Norwegian health care system has been published. 
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The primary objective is to investigate the effects of the intervention on rate of emergency medical visits (acute readmissions and visits to emergency departments (EDs)) 12 months after hospital discharge.
Secondary objectives include to investigate the effects on; self7reported HRQoL, acute readmissions, length of index hospital stay, time to first readmission, General practitioner (GP) visit rate, mortality rate, medication appropriateness, medication7related readmissions, medication changes, hip fracture rate and stroke rate.
This protocol is developed in accordance with the Standard Protocol Items: Recommendations for
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This is a non7blinded randomized controlled trial with an intervention group and a control group (1:1 ratio). The intervention group receives the intervention, while the control group receives standard care, see Figure 1 . Study enrolment started in September 2016.
-
0( $&1' #! "%+
The study is carried out at two acute internal medicine wards at the University Hospital of North7
Norway (UNN); a geriatric internal medicine ward at UNN Tromsø and a general acute internal medicine ward at UNN Harstad. The geriatric ward cares for older patients with complex acute medical needs and has consultants specialized in geriatric medicine. The general medicine ward treats patients admitted for stroke, pulmonary7, kidney7 and endocrine diseases as well as patients with geriatric concerns. 
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All acutely admitted patients are screened for eligibility and recruited by study pharmacists. Only eligible patients are invited to participate in the study. When written informed consent is obtained from patient or next of kin, the patient is included. Inclusion is only performed when a pharmacist is present. Readmitted study patients are not re7included, but receive standard care.
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Inclusion criteria: age ≥70 years, acutely admitted and willing to provide written informed consent (patient or next of kin). Exclusion criteria: admitted to the study ward more than 72 hours before evaluation of eligibility, moved to and discharged from other wards during the index stay, inability to understand Norwegian (patient or next of kin), considered terminally ill or with a short life expectancy, planned discharged on the inclusion day, occupying a bed in a study ward but under the care of physicians from a non7study ward, or if an intervention from a study pharmacist is considered necessary for ethical reasons (before randomization or in control group).
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After collecting baseline data, patients are randomized into the two study arms using a web7based service supplied by a third party. The randomization block sizes are concealed and permuted. We stratify by study site. As pharmacists are only involved in intervention patients, blinding of group allocation is impossible for both the patients, pharmacists and medical team. However, the primary analysis will be performed by an investigator blinded for group allocation.
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Patients assigned to standard care receive treatment from a team consisting of physicians, nurses, nurse assistants, sometimes occupational therapists and physiotherapists. Standard care may include elements as MedRec, medication review and patient counselling performed by physicians or nurses during the hospital stay. However, it is not standardized, structured or involving pharmacists. Study pharmacists are not involved in any clinical work concerning patients randomised to the control group.
Regarding MedRec at admission, this service is currently being implemented in hospitals nationwide as a part of the national patient safety program. The local hospital procedure at UNN states that MedRec should be performed by a physician at admittance, but local data show that adherence to the procedure is low (data not published). Local procedures for communication of medication information at hospital discharge requires that a discharge summary, including an updated medication list in addition to assessments, amendment and recommendations made during the hospital stay, is submitted Patients, for whom special home care is considered necessary, may be referred to a specialized patient care team before or at discharge. This team may include a pharmacist, which may supply pharmaceutical care services.
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Patients randomized to the intervention group receive the IMM7based intervention including: 1)
MedRec at admission, 2) medication review and monitoring during the hospital stay, 3) patient counselling designed to meet the needs of each individual patient, 4) MedRec at discharge together with an updated and structured medication list given to patients and submitted to primary care at discharge, and 5) a follow up phone call to the patients GP and nurses in home care service/nursing home to inform about and discuss current medication therapy and recommendations, see Figure 2 .
Step 5 is in addition to the original IMM model. The study pharmacist is performing all steps in close collaboration with the hospital physician who has the medical responsibility for the patients.
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MedRec is performed using a standardized MedRec tool developed in Sweden and adapted to Norwegian circumstances/conditions 21 29 . The tool facilitates information collection about the patient`s medication use and serves as documentation of information and information sources. It also includes questions about the patients practical handling and knowledge about medications, as well as medication adherence 21 29 . Patients that handle their own medication are interviewed if possible. If not, information about medication use is collected from other relevant sources, i.e. medication lists from GPs, national electronic medical records, local pharmacies, home care services, nursing homes or next of kin. These sources are also used to confirm medication information after patient interviews in case of uncertainties. Any adherence or medication information issues identified during MedRec is acted upon during patient counselling or at hospital discharge (Step 3).
During MedRec, the study pharmacists also perform a standardized symptom assessment to be used in
Step 2. This is done to identify possible adverse drug reactions, or possible targets for medication therapy improvements from a patient perspective. The assessment is performed to reveal if a patient Step Step 3: Patient counselling
For patients who will handle their own medication after discharge, a patient counselling session is arranged before discharge. The patients receive an updated medication list, which is discussed and explained. The pharmacists focuses upon changes made during the hospital stay and reasons for these changes. Patients are also encouraged to ask questions about their medications. Any medication adherence, handling or information issues identified during the hospital stay is also focused upon. If
This step does not replace the standard discharge meeting between the physician and the patient.
The discharge summary normally includes an updated overview of medications to be used after discharge. For intervention patients the study pharmacists draft this list in accordance with hospital procedures and the national patient safety program. They make sure it is reconciled, structured, and correct according to amendments done and contains information and explanations about medication 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 8 changes made during the hospital stay as well as recommendations and follow7up issues. The responsible ward physician uses this draft when preparing the discharge summary.
Within a week after discharge, the pharmacists calls the patient`s GP to inform about and discuss current medication therapy changes and recommendations stated in the discharge summary. The aim is to ensure that the changes and recommendations are implemented and acted upon
One the day of discharge, for patients where the home care services or the nursing home administer the patient`s medications, the pharmacists calls the responsible nurse to inform about medication changes, prescription and monitoring needs and other medication7related recommendations. Changes in multi7dosage dispensed medications are submitted to the local pharmacy responsible for dispensing the patient's medications in agreement with the home care services.
This step is not carried out for patients with no change in medications during the hospital stay and/or no identified need for follow up.
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Primary outcome
The primary outcome is the rate of the composite endpoint "acute readmissions and ED visits" 12 months after discharge from the index hospital stay in the intervention group compared with control group. An acute readmission is defined as any subsequent admission following the index admission excluding elective readmissions.
Secondary outcomes (intervention group compared with control group)
1. Change in self7reported health7related quality of life (HRQoL) from discharge to 1, 6 and 12 months after hospital discharge.
2. Length of index hospital stays.
3. Time to first acute readmission after discharge from index hospital stay (up to 12 months follow7 up).
The proportion of patients readmitted acutely within 30 days (a national quality indicator in
Norway).
5. GP visit rate during 12 months' follow7up.
6. Mortality rate during 12 months' follow7up.
7. Change in total score from admission to discharge of the Medication appropriateness index (MAI)
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10. Medication changes made during index hospital stay implemented by the GP at 3 and 12 months.
11. Number of medication7related first readmissions after index hospital stay.
12. Hip fracture rate during 12 months' follow7up.
13. Stroke rate during 12 months' follow7up #*2$ "3 '#$' $# "&% Sample size calculation for the primary outcome is based on a Swedish randomized controlled trial applying the same composite endpoint 12 . The Swedish trial investigated the effectiveness of interventions performed by ward7based pharmacists in reducing morbidity and use of hospital care among patients 80 years and older. They randomized 400 patients in a 1:1 relationship, and found a 16% reduction in all7cause visits to the hospital in the intervention group. If we estimate a rate of acute hospital admissions and ED visits of 1.7 per year in our control group, we need to enrol 456 patients (228 in each group) to detect a 16% reduction in hospital visits with a significance level of 5% and a power of 80%. To compensate for dropouts, we aim to include 250 patients in each group.
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Baseline
Baseline data for all study patients is collected before randomization to avoid collection bias. This include age, gender, smoking status, marital status, level of education, type and amount of help from home care services, and delivery of multi7dosage dispensed medications, medical diagnosis/medical history, weight, blood pressure, heart rate, relevant laboratory values (e.g. blood creatinine, C7reactive
protein, haemoglobin and glucose) and medication use at time of hospital admission. The latter is denoted in the handwritten medication chart as standard procedure in our hospitals, while all other information is found in the electronic patient journal.
Hospital stay
For the intervention group only, we collect outcome data from the intervention (e.g. discrepancies identified during MedRec, DRPs, physician agreement with regard to identified discrepancies or DRP, counselling issues etc.) during hospitalization and track communication between pharmacist, patients and health care workers in the ward and in primary care. For all study patients, we collect the following data from the discharge summary: discharge diagnose(s), laboratory results, medication list including description of changes during the hospital stay and recommendations to the next care level.
After discharge
Data collection of outcomes after discharge is identical for all study patients.
National registries
Data on readmissions (dates, lengths and reasons), ED visits (dates and reasons), GP visits (dates and reasons), deaths (date and reason), strokes (dates), hip fractures (dates and reasons) and dispensed medications will be collected from six Norwegian Health registries. These registries are, respectively:
The Norwegian Patient Registry (hospitalizations + ED visits), The Norwegian Health Economics Administration Registry (ED7 and GP visits), the National Cause of Death Registry, the Norwegian Stroke Registry, the Norwegian Hip Fracture Registry and the Norwegian Prescription Database (NorPD) holding information about all pharmacy dispensed medications in Norway. Linking data is possible through the unique personal identification number held by every Norwegian citizen. ED visits leading to a hospital stay will be counted as a hospital stay. We will collect data from all registries for the period 12 months before and 12 months after index hospital stay to enable adjustment for pre7study
patterns.
Medication use
In addition to the data on prescriptions collected from NorPD, updated lists of medications in use are collected from GP offices or nursing homes as appropriate at 3 and 12 months after hospital discharge.
Inappropriate prescribing
The medications lists at hospital admission, at discharge and at 3 and 12 months after discharge will retrospectively be subjected to application of the following scoring tools to identify possible inappropriate prescribing by an investigator blinded for group allocation: NORGEP7NH 31 
Medication7related readmissions
An interdisciplinary group of physicians and pharmacists will retrospectively assess whether the patient's first readmission was related to his/her medications and whether it could have been prevented. This will be performed blinded to group allocation.
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All data, except registry data, is entered manually into a Microsoft Access database. A random sample of patients will be drawn for control of data quality. Patient7ID is removed from all paper records and given consecutive study numbers. A list linking patient7IDs to study numbers is stored electronically on the hospital research server, separate from the Microsoft Access database. Only study personnel have access to the research server. Study papers used during work are kept at the hospital in accordance with hospital's patient protection routines.
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treat principles, and the reporting of results will follow the CONSORT guidelines 36 . All participants will be included in the analysis, regardless of whether the intervention was completed or not. A per protocol analysis will also be performed. Descriptive statistics for both study arms, and the total study population will be provided.
The primary analysis will be a Poisson regression of the rate of the composite end7point during 12 months after discharge between the two study groups. Censoring of study participants will be accounted for, and an adjustment for study site will be conducted. A two7sided alpha level of 5% will be used. We also plan to perform a secondary analysis of the primary endpoint using the proportion of patients fulfilling the composite endpoint and a survival analysis of the time to reach the composite end7point. In all analyses, adjustment for baseline variables will be conducted if appropriate.
We will analyse secondary outcomes applying appropriate statistical tests, e.g. comparison between study arms by logistic regression analysis for binary responses and using Cox proportional hazards 5% significance level will be applied, with no adjustments for multiplicity.
The amount of data collected allows for different subgroup analyses and include: to assess whether the effect of the intervention varies by: 1) number of medications at admission or discharge; 075, 6710, We will not expose the patient for any new clinical intervention that may put the patient at risk. In fact, some of the elements/procedures included in the intervention have already been shown to reduce drug7related readmissions, and visits to the ED 19 20 . Nevertheless, our intervention brings a new health7 care profession, the pharmacist, into the interdisciplinary team for whom the patient will have to relate to. We anticipate that patients feeling uncomfortable with this will refuse study participation.
We aim to publish study results in international peer7reviewed open access journals, at national and international conferences and as part of two PhD theses.
6 -
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Data collection methods 18a
Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol
9-11 18b
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